JP2014169326A5 - - Google Patents

Download PDF

Info

Publication number
JP2014169326A5
JP2014169326A5 JP2014121152A JP2014121152A JP2014169326A5 JP 2014169326 A5 JP2014169326 A5 JP 2014169326A5 JP 2014121152 A JP2014121152 A JP 2014121152A JP 2014121152 A JP2014121152 A JP 2014121152A JP 2014169326 A5 JP2014169326 A5 JP 2014169326A5
Authority
JP
Japan
Prior art keywords
antibody
ngf
pharmaceutical composition
use according
following
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2014121152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014169326A (ja
Filing date
Publication date
Priority claimed from US12/576,522 external-priority patent/US9260514B2/en
Application filed filed Critical
Publication of JP2014169326A publication Critical patent/JP2014169326A/ja
Publication of JP2014169326A5 publication Critical patent/JP2014169326A5/ja
Ceased legal-status Critical Current

Links

JP2014121152A 2009-10-09 2014-06-12 選択的ngf経路インヒビターとしてのヒト抗ngf中和抗体 Ceased JP2014169326A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/576,522 US9260514B2 (en) 2003-07-15 2009-10-09 Methods of treating conditions caused by increased expression of nerve growth factor (NGF) or increased sensitivity to NGF using anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
US12/576,522 2009-10-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012533344A Division JP2013507385A (ja) 2009-10-09 2010-10-08 選択的ngf経路インヒビターとしてのヒト抗ngf中和抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016206106A Division JP2017014286A (ja) 2009-10-09 2016-10-20 選択的ngf経路インヒビターとしてのヒト抗ngf中和抗体

Publications (2)

Publication Number Publication Date
JP2014169326A JP2014169326A (ja) 2014-09-18
JP2014169326A5 true JP2014169326A5 (enExample) 2015-06-18

Family

ID=43466840

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012533344A Pending JP2013507385A (ja) 2009-10-09 2010-10-08 選択的ngf経路インヒビターとしてのヒト抗ngf中和抗体
JP2014121152A Ceased JP2014169326A (ja) 2009-10-09 2014-06-12 選択的ngf経路インヒビターとしてのヒト抗ngf中和抗体
JP2016206106A Withdrawn JP2017014286A (ja) 2009-10-09 2016-10-20 選択的ngf経路インヒビターとしてのヒト抗ngf中和抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012533344A Pending JP2013507385A (ja) 2009-10-09 2010-10-08 選択的ngf経路インヒビターとしてのヒト抗ngf中和抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016206106A Withdrawn JP2017014286A (ja) 2009-10-09 2016-10-20 選択的ngf経路インヒビターとしてのヒト抗ngf中和抗体

Country Status (28)

Country Link
US (1) US9260514B2 (enExample)
EP (2) EP3028717A1 (enExample)
JP (3) JP2013507385A (enExample)
KR (1) KR101528393B1 (enExample)
CN (1) CN102762228A (enExample)
AR (1) AR078569A1 (enExample)
AU (2) AU2010308418A1 (enExample)
BR (1) BR112012008282A2 (enExample)
CA (1) CA2775924A1 (enExample)
CL (1) CL2012000881A1 (enExample)
CO (1) CO6541558A2 (enExample)
CR (1) CR20120198A (enExample)
EA (1) EA201290189A1 (enExample)
IL (1) IL218885A0 (enExample)
MA (1) MA33724B1 (enExample)
ME (1) ME00226B (enExample)
MT (1) MTP4289B (enExample)
MX (1) MX343748B (enExample)
MY (1) MY172283A (enExample)
NZ (2) NZ625391A (enExample)
PE (1) PE20121028A1 (enExample)
PH (1) PH12012500668A1 (enExample)
SG (1) SG10201603945RA (enExample)
TN (1) TN2012000136A1 (enExample)
TW (1) TW201125581A (enExample)
UA (1) UA102775C2 (enExample)
WO (1) WO2011049758A1 (enExample)
ZA (1) ZA201203135B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ES2514319T3 (es) * 2009-05-04 2014-10-28 Abbvie Research B.V. Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada
ES2665954T3 (es) * 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9783601B2 (en) * 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN111402950B (zh) * 2013-11-29 2024-03-19 豪夫迈·罗氏有限公司 抗体选择装置和方法
JP2018516112A (ja) 2015-04-17 2018-06-21 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. 異方性をもつ生物学的組織の検出
MA45890B2 (fr) 2016-11-29 2022-10-31 Regeneron Pharma Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes
EP3765516A2 (en) * 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
KR20210043624A (ko) * 2018-08-10 2021-04-21 리제너론 파아마슈티컬스, 인크. 무릎 및/또는 고관절 통증의 안전하고 효과적인 치료를 위한 약제학적 조성물
IT201800009384A1 (it) 2018-10-11 2020-04-11 Cosmo Srl Peptide for cosmetic application
CN113924315B (zh) * 2019-06-10 2022-06-28 山东博安生物技术股份有限公司 抗β-NGF纳米抗体及其应用
CN117050175B (zh) * 2020-04-17 2024-07-16 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN113549150A (zh) * 2020-04-26 2021-10-26 三生国健药业(上海)股份有限公司 结合人ngf的抗体、其制备方法和用途
WO2021238886A1 (en) * 2020-05-27 2021-12-02 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof
AU2020204105B2 (en) * 2020-06-19 2023-06-08 Dartsbio Pharmaceuticals Ltd. Anti-human ngf antibodies and methods using same
US11655292B2 (en) 2020-06-23 2023-05-23 Ampsource Biopharma Shanghai Inc. Anti-human NGF antibodies and methods using same
IT202000020287A1 (it) * 2020-08-20 2022-02-20 Colosseum Combinatorial Chemistry Centre For Tech Societa A Responsabilita Limitata In Forma Abbrevi Peptide per applicazioni terapeutiche in campo dermatologico
WO2023092052A1 (en) 2021-11-19 2023-05-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
AR128311A1 (es) * 2022-01-21 2024-04-17 Inst Pasteur De Montevideo Inmunización activa para reducir el dolor osteoarticular, neuropático y en cáncer
US20240002491A1 (en) 2022-04-27 2024-01-04 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist
FR3148027A1 (fr) * 2023-04-24 2024-10-25 Peptinov Composition vaccinale anti-ngf
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US913242A (en) 1905-08-29 1909-02-23 Electrelle Company Automatic music-playing attachment for pianos.
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4230691A (en) 1978-05-23 1980-10-28 The Massachusetts General Hospital Nerve growth factor antibody and process
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4710473A (en) 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4786593A (en) 1985-04-16 1988-11-22 Wistar Institute Of Anatomy And Biology Diagnostic method for detection of neural crest disease
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
JP2969647B2 (ja) 1988-09-14 1999-11-02 東ソー株式会社 モノクローナル抗体、それからなる阻害剤及びそれを用いた測定方法
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE465573B (sv) 1989-03-14 1991-09-30 Lope Medicine Ab Nervtillvaextfaktorpeptider, motsvarande antikroppar och foerfarande foer bestaemning av nativ nervtillvaextfaktor
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
EP0418590B1 (en) 1989-08-28 1997-11-19 Takeda Chemical Industries, Ltd. Antibodies, production thereof and use
US5656435A (en) 1989-08-28 1997-08-12 Takeda Chemical Industries, Ltd. Antibodies to peptides having NGF-like activity, said antibodies having no substantial cross-reactivity with NGF, and use thereof
JPH03163095A (ja) 1989-08-28 1991-07-15 Takeda Chem Ind Ltd ヒト神経成長因子の部分ペプチド、抗体およびその用途
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP3232415B2 (ja) 1990-08-29 2001-11-26 武田薬品工業株式会社 モノクローナル抗体,その製造法および用途
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH06317587A (ja) 1990-08-31 1994-11-15 Takeda Chem Ind Ltd 抗体およびその用途
US5147294A (en) 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
JPH06508035A (ja) 1991-06-14 1994-09-14 ディーエヌエックス コーポレーション トランスジェニックブタにおけるヒトヘモグロビンの生産
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
JPH0576384A (ja) 1991-09-20 1993-03-30 Hitachi Ltd 抗ヒト神経成長因子モノクローナル抗体
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム インターナショナル,インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
JP3519096B2 (ja) 1992-07-02 2004-04-12 武田薬品工業株式会社 モノクローナル抗体、ハイブリドーマおよびそれらの用途
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9616105D0 (en) 1996-07-31 1996-09-11 Univ Kingston TrkA binding site of NGF
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
BR0009323A (pt) 1999-03-25 2002-01-08 Knoll Gmbh Anticorpos humanos que ligam a il-12 humana e métodos para a produção
CN1399645A (zh) 1999-07-29 2003-02-26 米德列斯公司 Her2/neu的人单克隆抗体
EP2110138A1 (en) 1999-08-27 2009-10-21 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
KR20100132559A (ko) 2001-05-30 2010-12-17 제넨테크, 인크. 다양한 질환의 치료에 유용한 항-엔지에프 항체
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
EP1369431A4 (en) 2001-10-15 2005-01-12 Kirin Brewery ANTI-HLA-DR ANTIBODIES
EP1467756A4 (en) 2001-12-28 2007-03-21 Abgenix Inc METHODS OF USING ANTI-MUC18 ANTIBODIES
US6919426B2 (en) * 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
WO2004032870A2 (en) 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
DK1575517T3 (da) 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
KR100894191B1 (ko) * 2003-07-15 2009-04-22 암젠 인코포레이티드 선택적인 ngf 경로 저해제로서의 인체 항-ngf 중화 항체 및 이 항체를 포함하는 약학적 조성물
UA97086C2 (uk) * 2003-07-15 2012-01-10 Емджен, Інк. Виділене людське антитіло, яке специфічно зв'язується з фактором росту нервової тканини (ngf)
JP5096167B2 (ja) 2005-01-24 2012-12-12 メドイミューン リミテッド Ngfに対する特異的結合メンバー
WO2013180295A1 (ja) 2012-06-01 2013-12-05 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Similar Documents

Publication Publication Date Title
NZ625391A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
JP2014502955A5 (enExample)
EA201991316A1 (ru) Конъюгаты, содержащие двойной агонист glp-1/глюкагона, линкер и гиалуроновую кислоту
RU2012137498A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
AR088458A1 (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y fingolimod
HRP20210250T1 (hr) Učinkovita i djelotvorna kontrola serumskog fosfata za optimalno stvaranje kostiju
UA113626C2 (xx) Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
JP2016502515A5 (enExample)
RU2012156938A (ru) Антитела против gdf8 человека
RU2017119647A (ru) Способ лечения болезней глаз
RU2012122162A (ru) Гликолизированная форма аналога антигенного glp-1
RU2017107559A (ru) Лечение раковых заболеваний с применением анти-nkg2a средств
RU2013102225A (ru) АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2013538796A5 (enExample)
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
JP2020510039A5 (enExample)
JP2015513903A5 (enExample)
RU2011142183A (ru) Средство для лечения ревматоидного артрита
MX355611B (es) Formulaciones de anticuerpos monoclonales de alta concentracion.
EP4606430A3 (en) Use of il-22 dimer in manufacture of a medicament for intravenous administration
JP2013533268A5 (enExample)
CN104245736A (zh) 抗人死亡受体5胞外区的人源化单克隆抗体
JP2018529661A5 (enExample)
JP2015510882A5 (enExample)
IL278717B1 (en) Starting dose of pth conjugates